The University of Southampton
University of Southampton Institutional Repository

One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence

One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence
One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence

One hundred and ten years after Noon's first clinical report of the subcutaneous application of allergen extracts, allergen immunotherapy (AIT) has evolved as the most important pillar of the treatment of allergic patients. It is the only disease-modifying treatment option available and the evidence for its clinical efficacy and safety is broad and undisputed. Throughout recent decades, more insights into the underlying mechanisms, in particular the modulation of innate and adaptive immune responses, have been described. AIT is acknowledged by worldwide regulatory authorities, and following the regulatory guidelines for product development, AIT products are subject to a rigorous evaluation before obtaining market authorization. Knowledge and practice are anchored in international guidelines, such as the recently published series of the European Academy of Allergy and Clinical Immunology (EAACI). Innovative approaches continue to be further developed with the focus on clinical improvement by, for example, the usage of adjuvants, peptides, recombinants, modification of allergens, new routes of administration, and the concomitant use of biologicals. In addition, real-life data provide complementary and valuable information on the effectiveness and tolerability of this treatment option in the clinical routine. New mobile health technologies and big-data approaches will improve daily treatment convenience, adherence, and efficacy of AIT. However, the current coronavirus disease 2019 (COVID-19) pandemic has also had some implications for the feasibility and practicability of AIT. Taken together, AIT as the only disease-modifying therapy in allergic diseases has been broadly investigated over the past 110 years laying the path for innovations and further improvement.

allergen immunotherapy, allergic rhinitis, evidence, innovations, mechanisms
0105-4538
Pfaar, O
85c41012-6b31-4ab5-bc5a-bc89d094e3c4
Bousquet, J
fda25127-be6f-45cd-a455-883cc90d8e0e
Durham, S R
2c4a2deb-84be-4796-9566-fdcddfe29d8b
Kleine-Tebbe, J
37b07cf7-30c3-4c64-9429-d302e05bd008
Larché, M
93db85ef-0a8c-48c1-8f86-98dd9536a5b7
Roberts, G
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Shamji, M H
d68ff179-5c3e-466e-b3d0-07cb3414e618
Gerth van Wijk, R
64d21a3b-ed5a-46ae-a2d2-35478f0ea484
Pfaar, O
85c41012-6b31-4ab5-bc5a-bc89d094e3c4
Bousquet, J
fda25127-be6f-45cd-a455-883cc90d8e0e
Durham, S R
2c4a2deb-84be-4796-9566-fdcddfe29d8b
Kleine-Tebbe, J
37b07cf7-30c3-4c64-9429-d302e05bd008
Larché, M
93db85ef-0a8c-48c1-8f86-98dd9536a5b7
Roberts, G
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Shamji, M H
d68ff179-5c3e-466e-b3d0-07cb3414e618
Gerth van Wijk, R
64d21a3b-ed5a-46ae-a2d2-35478f0ea484

Pfaar, O, Bousquet, J, Durham, S R, Kleine-Tebbe, J, Larché, M, Roberts, G, Shamji, M H and Gerth van Wijk, R (2021) One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence. Allergy. (doi:10.1111/all.15023).

Record type: Review

Abstract

One hundred and ten years after Noon's first clinical report of the subcutaneous application of allergen extracts, allergen immunotherapy (AIT) has evolved as the most important pillar of the treatment of allergic patients. It is the only disease-modifying treatment option available and the evidence for its clinical efficacy and safety is broad and undisputed. Throughout recent decades, more insights into the underlying mechanisms, in particular the modulation of innate and adaptive immune responses, have been described. AIT is acknowledged by worldwide regulatory authorities, and following the regulatory guidelines for product development, AIT products are subject to a rigorous evaluation before obtaining market authorization. Knowledge and practice are anchored in international guidelines, such as the recently published series of the European Academy of Allergy and Clinical Immunology (EAACI). Innovative approaches continue to be further developed with the focus on clinical improvement by, for example, the usage of adjuvants, peptides, recombinants, modification of allergens, new routes of administration, and the concomitant use of biologicals. In addition, real-life data provide complementary and valuable information on the effectiveness and tolerability of this treatment option in the clinical routine. New mobile health technologies and big-data approaches will improve daily treatment convenience, adherence, and efficacy of AIT. However, the current coronavirus disease 2019 (COVID-19) pandemic has also had some implications for the feasibility and practicability of AIT. Taken together, AIT as the only disease-modifying therapy in allergic diseases has been broadly investigated over the past 110 years laying the path for innovations and further improvement.

Text
Allergy - 2021 - Pfaar - One hundred and ten years of Allergen Immunotherapy A journey from empiric observation to - Version of Record
Download (1MB)

More information

Accepted/In Press date: 24 July 2021
e-pub ahead of print date: 27 September 2021
Keywords: allergen immunotherapy, allergic rhinitis, evidence, innovations, mechanisms

Identifiers

Local EPrints ID: 453796
URI: http://eprints.soton.ac.uk/id/eprint/453796
ISSN: 0105-4538
PURE UUID: 853472d8-aa60-4c4f-8dde-92b0b884117e
ORCID for G Roberts: ORCID iD orcid.org/0000-0003-2252-1248

Catalogue record

Date deposited: 24 Jan 2022 17:50
Last modified: 17 Mar 2024 03:02

Export record

Altmetrics

Contributors

Author: O Pfaar
Author: J Bousquet
Author: S R Durham
Author: J Kleine-Tebbe
Author: M Larché
Author: G Roberts ORCID iD
Author: M H Shamji
Author: R Gerth van Wijk

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×